{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:07:11Z","timestamp":1789470431607,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-026-01631-1","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:49:43Z","timestamp":1789469383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Parthenolide enhances imatinib activity in gastrointestinal stromal tumor models through stress-associated apoptosis"],"prefix":"10.1007","author":[{"given":"Chuang-Ming","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longyi","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggen","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toufeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"1631_CR1","doi-asserted-by":"publisher","first-page":"175883592311923","DOI":"10.1177\/17588359231192388","volume":"15","author":"C Serrano","year":"2023","unstructured":"Serrano C, Mart\u00edn-Broto J, Asencio-Pascual JM et al (2023) 2023 GEIS Guidelines for gastrointestinal stromal tumors. Ther Adv Med Oncol 15:17588359231192388. https:\/\/doi.org\/10.1177\/17588359231192388","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"1631_CR2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472\u2013480. https:\/\/doi.org\/10.1056\/NEJMoa020461","journal-title":"N Engl J Med"},{"issue":"6","key":"1631_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41416-019-0389-6","volume":"120","author":"C Serrano","year":"2019","unstructured":"Serrano C, Mari\u00f1o-Enr\u00edquez A, Tao DL et al (2019) Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer 120(6):612\u2013620. https:\/\/doi.org\/10.1038\/s41416-019-0389-6","journal-title":"Br J Cancer"},{"issue":"11","key":"1631_CR4","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s11864-024-01272-7","volume":"25","author":"C He","year":"2024","unstructured":"He C, Wang Z, Yu J, Mao S, Xiang X (2024) Current drug resistance mechanisms and treatment options in gastrointestinal stromal tumors: summary and update. Curr Treat Options Oncol 25(11):1390\u20131405. https:\/\/doi.org\/10.1007\/s11864-024-01272-7","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"1631_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"JY Blay","year":"2020","unstructured":"Blay JY, Serrano C, Heinrich MC et al (2020) Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 21(7):923\u2013934. https:\/\/doi.org\/10.1016\/S1470-2045(20)30168-6","journal-title":"Lancet Oncol"},{"issue":"7","key":"1631_CR6","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","volume":"21","author":"MC Heinrich","year":"2020","unstructured":"Heinrich MC, Jones RL, von Mehren M et al (2020) Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 21(7):935\u2013946. https:\/\/doi.org\/10.1016\/S1470-2045(20)30269-2","journal-title":"Lancet Oncol"},{"issue":"32","key":"1631_CR7","doi-asserted-by":"publisher","first-page":"14333","DOI":"10.1073\/pnas.1000248107","volume":"107","author":"A Gupta","year":"2010","unstructured":"Gupta A, Roy S, Lazar AJF et al (2010) Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci U S A 107(32):14333\u201314338. https:\/\/doi.org\/10.1073\/pnas.1000248107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1631_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03650-7","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang J, Chen K, Tang Y et al (2021) LncRNA-HOTAIR activates autophagy and promotes the imatinib resistance of gastrointestinal stromal tumor cells through a mechanism involving the miR-130a\/ATG2B pathway. Cell Death Dis 12(4). https:\/\/doi.org\/10.1038\/s41419-021-03650-7","journal-title":"Cell Death Dis"},{"key":"1631_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215639","volume":"535","author":"B Ni","year":"2022","unstructured":"Ni B, Li Q, Zhuang C et al (2022) The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux. Cancer Lett 535. https:\/\/doi.org\/10.1016\/j.canlet.2022.215639","journal-title":"Cancer Lett"},{"issue":"5","key":"1631_CR10","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.4103\/jcrt.jcrt_625_22","volume":"18","author":"S Sui","year":"2022","unstructured":"Sui S, Ma F, Mi L et al (2022) Circ-CCS enhances autophagy during imatinib resistance of gastrointestinal stromal tumor by regulating miR-197-3p\/ATG10 signaling. J Cancer Res Ther 18(5):1338\u20131345. https:\/\/doi.org\/10.4103\/jcrt.jcrt_625_22","journal-title":"J Cancer Res Ther"},{"issue":"8","key":"1631_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ph13080194","volume":"13","author":"M Sztiller-Sikorska","year":"2020","unstructured":"Sztiller-Sikorska M, Czyz M (2020) Parthenolide as cooperating agent for anti-cancer treatment of various malignancies. Pharmaceuticals (Basel) 13(8). https:\/\/doi.org\/10.3390\/ph13080194","journal-title":"Pharmaceuticals (Basel)"},{"key":"1631_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2147\/DDDT.S355059","volume":"16","author":"T An","year":"2022","unstructured":"An T, Yin H, Lu Y, Liu F (2022) The emerging potential of parthenolide nanoformulations in tumor therapy. Drug Des Devel Ther 16:1255\u20131272. https:\/\/doi.org\/10.2147\/DDDT.S355059","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"1631_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119167","volume":"24","author":"J Jorge","year":"2023","unstructured":"Jorge J, Neves J, Alves R, Geraldes C, Gon\u00e7alves AC, Sarmento-Ribeiro AB (2023) Parthenolide induces ROS-mediated apoptosis in lymphoid malignancies. Int J Mol Sci 24(11). https:\/\/doi.org\/10.3390\/ijms24119167","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1631_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3892\/or.2021.7933","volume":"45","author":"X Fu","year":"2021","unstructured":"Fu X, Cui J, Meng X et al (2021) Endoplasmic reticulum stress, cell death and tumor: association between endoplasmic reticulum stress and the apoptosis pathway in tumors (review). Oncol Rep 45(3):801\u2013808. https:\/\/doi.org\/10.3892\/or.2021.7933","journal-title":"Oncol Rep"},{"issue":"1","key":"1631_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41420-024-02110-3","volume":"10","author":"W Zhang","year":"2024","unstructured":"Zhang W, Shi Y, Oyang L et al (2024) Endoplasmic reticulum stress-a key guardian in cancer. Cell Death Discov 10(1):343. https:\/\/doi.org\/10.1038\/s41420-024-02110-3","journal-title":"Cell Death Discov"},{"issue":"11","key":"1631_CR16","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.17219\/acem\/175152","volume":"33","author":"D Han","year":"2024","unstructured":"Han D, Zhu W, Chen Y, Wang H (2024) Parthenolide induces ROS-dependent cell death in human gastric cancer cell. Adv Clin Exp Med Off Organ Wroclaw Med Univ 33(11):1237\u20131245. https:\/\/doi.org\/10.17219\/acem\/175152","journal-title":"Adv Clin Exp Med Off Organ Wroclaw Med Univ"},{"key":"1631_CR17","doi-asserted-by":"publisher","first-page":"6433","DOI":"10.2147\/OTT.S256935","volume":"13","author":"S Zheng","year":"2020","unstructured":"Zheng S, Shu Y, Lu Y, Sun Y (2020) Chloroquine combined with imatinib overcomes imatinib resistance in gastrointestinal stromal tumors by inhibiting autophagy via the MAPK\/ERK pathway. OncoTargets Ther 13:6433\u20136441. https:\/\/doi.org\/10.2147\/OTT.S256935","journal-title":"OncoTargets Ther"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01631-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01631-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01631-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:49:43Z","timestamp":1789469383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01631-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":17,"alternative-id":["1631"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01631-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal experiment was approved by the Laboratory Animal Ethics Committee of Yanbian University (approval no. YD20240311016). All procedures were performed in accordance with the Yanbian University Laboratory Animal Management Rules.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}